<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of sentinel lymph node biopsy in breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of sentinel lymph node biopsy in breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of sentinel lymph node biopsy in breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seth P Harlow, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald L Weaver, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Hayes, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lori J Pierce, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The status of the axillary lymph nodes is one of the most important prognostic factors in patients with breast cancer. Histologic examination of lymph nodes is the most accurate method for assessing lymph node metastasis; approximately one in four patients with clinically negative lymph nodes will have pathologically identified nodal metastases. When the axilla is clinically negative by palpation and ultrasound examination, the pathologic node-positive rate decreases to approximately 18 percent. </p><p>Axillary dissection has traditionally been used in breast surgery to obtain lymph nodes. Sentinel lymph node biopsy has replaced axillary lymph node dissection in most patients with early breast cancer. (See  <a class="medical medical_review" href="/d/html/813.html" rel="external">"Overview of management of the regional lymph nodes in breast cancer"</a> and  <a class="medical medical_review" href="/d/html/88415.html" rel="external">"Prognostic and predictive factors in metastatic breast cancer", section on 'Prognostic versus predictive factors'</a>.)</p><p>Indications for and outcomes of sentinel lymph node biopsy will be reviewed here. The technique of sentinel lymph node mapping in patients with breast cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/805.html" rel="external">"Sentinel lymph node biopsy in breast cancer: Techniques"</a>.)</p><p class="headingAnchor" id="H1816667"><span class="h1">PREOPERATIVE AXILLA EVALUATION</span><span class="headingEndMark"> — </span>It is essential that patients receive adequate evaluation of the axilla prior to surgery. Preoperative evaluation of axillary lymph nodes separates patients into two categories: patients with clinically positive nodes typically undergo axillary lymph node dissection (ALND), and patients with clinically negative nodes may undergo sentinel lymph node biopsy (SLNB)  (<a class="graphic graphic_algorithm graphicRef139027" href="/d/graphic/139027.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/813.html" rel="external">"Overview of management of the regional lymph nodes in breast cancer", section on 'Axillary management'</a>.)</p><p>There may be some exceptions in patients who receive and have a good response to neoadjuvant therapy. (See  <a class="medical medical_review" href="/d/html/14225.html" rel="external">"General principles of neoadjuvant management of breast cancer", section on 'Node evaluation'</a>.)</p><p class="headingAnchor" id="H1509868350"><span class="h1">PATIENT SELECTION</span></p><p class="headingAnchor" id="H3"><span class="h2">Indications</span><span class="headingEndMark"> — </span>We recommend the use of sentinel lymph node biopsy (SLNB) to assess axillary lymph nodes in patients with early breast cancer (T1 or T2) who have clinically negative nodes and in patients with ductal carcinoma in situ (DCIS) when mastectomy is performed. These recommendations are consistent with those made by the American Society of Clinical Oncology in 2014 [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H168323"><span class="h3">Early breast cancer with clinically negative nodes</span><span class="headingEndMark"> — </span>SLNB should be performed in women with clinically node-negative early breast cancer [<a href="#rid2">2</a>]. For these patients, SLNB is a method of staging the axilla with less morbidity than axillary lymph node dissection (ALND). Patients with negative pathology results from fine needle aspirate or core biopsy of imaging-detected abnormal lymph nodes should also be considered for SLNB.</p><p class="headingAnchor" id="H168329"><span class="h3">DCIS with planned mastectomy or suspicious features</span><span class="headingEndMark"> — </span>Most women with DCIS do <strong>not</strong> require assessment of the axillary nodes, because DCIS is not invasive cancer and does not metastasize. However, two groups of women undergoing breast surgery for DCIS may benefit from SLNB.</p><p class="headingAnchor" id="H268704"><span class="h4">DCIS with planned mastectomy</span><span class="headingEndMark"> — </span>SLNB should be performed in all patients with DCIS undergoing total mastectomy. The technique of SLNB involves injecting radiolabeled tracer into the breast parenchyma near the area of DCIS or, alternatively, in a periareolar location. After a total mastectomy, the lymphatic drainage pattern will be permanently altered, making it impossible to accurately perform SLNB at a later date if invasive cancer is found unexpectedly in the mastectomy specimen [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H268710"><span class="h4">DCIS with suspicious features</span><span class="headingEndMark"> — </span>Some also recommend SLNB to patients undergoing breast-conserving surgery for DCIS clinically suspected of harboring invasive cancer, including DCIS larger than 5 cm and DCIS with a palpable mass. Offering SLNB with breast-conserving surgery to DCIS patients who have a high clinical or pathological suspicion of synchronous invasive cancer may spare them the inconvenience of a second operation. In a study of over 15,000 women undergoing breast-conserving surgery for DCIS, 18 percent underwent SLNB; metastatic disease was found in 0.9 percent of those who underwent SLNB [<a href="#rid4">4</a>].</p><p>The practice of performing SLNB with breast-conserving surgery for DCIS is controversial [<a href="#rid1">1</a>]. Invasive carcinoma has only been reported in 10 to 20 percent of excision specimens following a biopsy diagnosis of DCIS [<a href="#rid5">5</a>]. Thus, most women will not have any invasive disease on final pathology. For them, omitting SLNB at the time of their breast-conserving surgery eliminates any perioperative morbidity associated with SLNB [<a href="#rid6">6-8</a>]. If invasive breast cancer is identified after a breast-conserving surgery is performed for DCIS, SLNB can be performed as a second procedure to stage the axilla. Disease stage and subsequent axillary management may change for such patients [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/d/html/14219.html" rel="external">"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14220.html" rel="external">"Ductal carcinoma in situ: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/14221.html" rel="external">"Microinvasive breast carcinoma"</a> and  <a class="medical medical_review" href="/d/html/800.html" rel="external">"Tumor, node, metastasis (TNM) staging classification for breast cancer"</a>.)</p><p>A new strategy for patients with high-risk DCIS has been proposed using superparamagnetic iron oxide (SPIO), a novel tracer agent. In a proof-of-concept study (SentiNot) [<a href="#rid9">9</a>], investigators injected SPIO at the time of mastectomy or breast-conserving surgery for patients with high-risk DCIS. The SPIO signal persisted for up to one month after injection, and a sentinel node biopsy was then performed if invasive carcinoma was found on the final specimen. In this small study, the SPIO plus blue dye outperformed isotope and blue dye in detecting sentinel nodes, and sentinel node biopsy was avoided in 78 percent of patients when invasive carcinoma was not identified in the final breast specimen. It should be noted that these data are preliminary, but if such a strategy is proven to be effective in prospective studies, it may be an alternative axillary management strategy in patients with high-risk DCIS. This would, however, require all patients to be injected with the SPIO, which can lead to skin discoloration in up to 22 percent of patients per their report. Peritumoral injection reduced staining compared with retroareolar injection without affecting detection rate [<a href="#rid10">10</a>]. Rare anaphylactic reactions may occur [<a href="#rid11">11</a>], and residual iron oxide particles in the breast may induce mammographic abnormalities [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H64313104"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Clinically positive nodes and inflammatory breast cancer (T4d) are absolute contraindications for SLNB; both should be treated with ALND [<a href="#rid1">1</a>]. Locally advanced breast cancer is a relative contraindication for SLNB. Certain large tumors (eg, T3) may be amenable to SLNB, while others with skin or chest wall involvement (eg, T4a-c) should be treated with ALND (see  <a class="medical medical_review" href="/d/html/800.html" rel="external">"Tumor, node, metastasis (TNM) staging classification for breast cancer", section on 'Primary tumor classification'</a>). Additionally, SLNB should be omitted in patients whose axillary status does not guide adjuvant therapy. </p><p class="headingAnchor" id="H841746368"><span class="h3">Clinically positive nodes</span><span class="headingEndMark"> — </span>We recommend that patients who have clinically positive nodes that have been pathologically proven to contain metastatic cancer should undergo ALND for axillary clearance, rather than SLNB.</p><p>Those who undergo neoadjuvant therapy should be reevaluated for the suitability of SLNB prior to surgery. (See  <a class="medical medical_review" href="/d/html/14225.html" rel="external">"General principles of neoadjuvant management of breast cancer", section on 'Post-treatment evaluation and management'</a>.)</p><p class="headingAnchor" id="H665291959"><span class="h3">Locally advanced and inflammatory breast cancer</span><span class="headingEndMark"> — </span>The 2014 American Society of Clinical Oncology and the 2010 International Expert Panel guidelines on SLNB recommend <strong>against</strong> the use of SLNB in patients with locally advanced or inflammatory breast cancer [<a href="#rid1">1,6,13</a>]. ALND is recommended for this group of patients to maximize locoregional control [<a href="#rid6">6</a>].</p><p>Since larger tumors have a higher likelihood of axillary node metastases, most trials have restricted SLNB use to T1 or T2 breast cancers (&lt;5 cm). However, some studies have shown that SLNB can be accurate in patients with T3 tumors and clinically negative axilla [<a href="#rid14">14,15</a>]. Thus, many clinicians, including the authors of this topic, do not recognize tumor size of larger than 5 cm (T3) as an absolute contraindication to SLNB, as long as the axilla is clinically negative. </p><p>Patients with locally advanced tumors with skin and/or chest wall involvement (T4a-c) or inflammatory breast cancer (T4d) are <strong>not</strong> candidates for SLNB [<a href="#rid16">16,17</a>]. The false negative rate is high in such patients, presumably because of partially obstructed and/or functionally abnormal subdermal lymphatics.</p><p class="headingAnchor" id="H2966213834"><span class="h3">Patients whose axillary status does not guide adjuvant treatment</span><span class="headingEndMark"> — </span>We do not consider advanced age an absolute contraindication to SLNB in women with breast cancer, as age has never been shown to influence the accuracy, safety, and value of SLNB. However, SLNB should be omitted if the nodal information gained through the procedure will not affect adjuvant treatment decisions.</p><p>We suggest that the decision to omit SLNB in older women be made in a multidisciplinary setting with input from the treating medical and radiation oncologists to ensure all providers are in agreement as to whether or not axillary staging information is important for adjuvant therapy decisions. The management of early breast cancer in older women is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/757.html" rel="external">"Overview of the approach to early breast cancer in older women", section on 'Management of the axilla'</a>.) </p><p class="headingAnchor" id="H5597727"><span class="h2">Special circumstances</span><span class="headingEndMark"> — </span>Although SLNB has been performed in the following special circumstances, its use remains controversial and not universally accepted [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H5597935"><span class="h3">Neoadjuvant chemotherapy</span><span class="headingEndMark"> — </span>Neoadjuvant systemic therapy is the accepted approach for women with locally advanced breast cancer, women with inflammatory breast cancer, and women who have operable breast cancer but desire breast-conserving surgery. It is controversial whether SLNB or ALND should be performed and whether it should be performed prior to or following the completion of neoadjuvant chemotherapy in such patients. This issue is further discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/14225.html" rel="external">"General principles of neoadjuvant management of breast cancer", section on 'Node evaluation'</a>.)</p><p class="headingAnchor" id="H5597953"><span class="h3">Multicentric disease</span><span class="headingEndMark"> — </span>Multicentric disease is not a contraindication to SLNB [<a href="#rid1">1</a>]. Studies of breast lymphatic drainage indicate that all quadrants of the breast drain into the same lymph node(s) [<a href="#rid18">18,19</a>]. Thus, subareolar and intradermal (rather than peritumoral) injection of radiolabeled colloid or blue dye makes SLNB feasible for patients with multicentric disease [<a href="#rid18">18,20-22</a>]. (See  <a class="medical medical_review" href="/d/html/805.html" rel="external">"Sentinel lymph node biopsy in breast cancer: Techniques"</a>.)</p><p>Successful SLNB for multicentric disease has been demonstrated by several studies [<a href="#rid21">21,23</a>]. In one study of 142 women with multicentric breast cancer, SLNB was successful in 91 percent of patients, with a false negative rate of 4 percent [<a href="#rid23">23</a>]. However, more patients undergo completion ALND after SLNB in multicentric compared with unicentric disease. The likelihood of finding additional disease at the time of completion ALND is also higher with multicentric disease.</p><p class="headingAnchor" id="H5605226"><span class="h3">Previous breast and axillary procedures for benign conditions</span><span class="headingEndMark"> — </span>Two studies have demonstrated the feasibility and accuracy of SLNB in patients who had prior excisional breast biopsy [<a href="#rid24">24,25</a>]. However, it is unclear whether women who have undergone cosmetic breast surgeries, such as reduction mammoplasty or breast augmentation, can undergo SLNB. Patients who have had extensive breast or axillary surgery may have disruption or alteration to the normal pattern of lymphatic drainage, which may increase the false negative rate of SLNB. Thus, in these patients, we perform preoperative lymphoscintigraphy prior to SLNB. (See  <a class="medical medical_review" href="/d/html/805.html" rel="external">"Sentinel lymph node biopsy in breast cancer: Techniques"</a>.)</p><p class="headingAnchor" id="H5598145"><span class="h3">Recurrent breast cancer and previous axillary procedures</span><span class="headingEndMark"> — </span>SLNB after previous axillary surgery has not been widely studied. However, there are accumulating reports of successful second SLNB in patients with local recurrences of breast cancer following a previous SLNB or ALND [<a href="#rid26">26-29</a>]. </p><p>In women who were previously treated with breast-conserving therapy and have in-breast recurrence or a new ipsilateral breast cancer, we perform a lymphoscintigraphy to identify the sentinel node(s) before attempting a repeat SLNB. </p><p>Technical failure rates and false negative rates of an SLNB in this setting are related to the extent of previous axillary surgery and are in general higher compared with those of an initial SLNB. Although the success rate of identifying a sentinel node may be lower with prior axillary surgery, SLNB can be as accurate as in patients without prior axillary surgery when a sentinel node can be identified [<a href="#rid30">30-34</a>]. (See  <a class="medical medical_review" href="/d/html/128421.html" rel="external">"Surgery and radiation for locoregional recurrences of breast cancer", section on 'Surgical management'</a>.)</p><p class="headingAnchor" id="H12039554"><span class="h3">Male breast cancer</span><span class="headingEndMark"> — </span>The vast majority of published studies of SLNB for breast cancer were done in women. Data are limited in men with breast cancer because they are uncommon, and most male breast cancers are treated with mastectomy rather than breast-conserving surgery. </p><p>Prospective studies establishing the sensitivity and specificity of SLNB in male breast cancer patients have not been carried out. However, we feel it is acceptable to proceed with SLNB in men and that the principles guiding SLNB in women appear to apply to men. (See  <a class="medical medical_review" href="/d/html/779.html" rel="external">"Breast cancer in men", section on 'Management of the regional nodes'</a>.)</p><p class="headingAnchor" id="H171139"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>SLNB is best avoided in women who are pregnant because of potential teratogenic effects on the developing fetus from <a class="drug drug_general" data-topicid="9039" href="/d/drug information/9039.html" rel="external">isosulfan blue dye</a> and a lack of safety studies on other tracer agents [<a href="#rid1">1</a>]. Also, it is not clear whether lymphatic pathways in the breasts of pregnant women are altered, making identification of the sentinel node more difficult. </p><p>Although some consider the use of <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a> or radioactive colloid to be safe for the fetus in pregnant women with breast cancer, <a class="drug drug_general" data-topicid="9039" href="/d/drug information/9039.html" rel="external">isosulfan blue dye</a> (Lymphazurin) is systemically absorbed after subcutaneous injection and therefore should not be used during pregnancy [<a href="#rid35">35,36</a>]. </p><p>When axillary surgery is necessary during pregnancy, limited data suggest that SLNB can be performed, but with radioactive colloid alone, which is not teratogenic at the dose administered for SLNB. Some authors suggest that SLNB is safe in pregnant patients with a minimal dose of 500 to 600 microCurie using double-filtered technetium sulfur colloid, but no supporting studies for this approach are available [<a href="#rid37">37,38</a>]. Others, by deriving estimates of absorbed dose at the level of the epigastrium, umbilicus, and hypogastrium in nonpregnant women undergoing sentinel node biopsy for breast cancer, have concluded that expected levels of fetal exposure would be below the 50 milligray (mGy) threshold absorbed dose for adverse effects [<a href="#rid39">39,40</a>]. </p><p>Small series of SLNB in pregnant patients have reported successful sentinel lymph node mapping with no apparent adverse effects [<a href="#rid36">36,41</a>]. In one retrospective study, 25 pregnant women with breast cancer were injected with <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a> (7), radioactive colloid (16), or another type of tracer (2) during SLNB procedures [<a href="#rid42">42</a>]. There were 25 livebirth infants, 24 of whom were deemed healthy at delivery; one infant had a cleft lip not attributed to the injections. At 2.5 years, no adverse outcomes were attributed to the injection. </p><p class="headingAnchor" id="H168849"><span class="h1">VALIDATION AND PATHOLOGY</span><span class="headingEndMark"> — </span>Sentinel lymph node biopsy (SLNB) utilizes the lymphatic mapping technique to locate and remove one or more (on average, three) axillary lymph nodes in patients with breast cancer [<a href="#rid43">43</a>]. The sentinel lymph nodes are then submitted for pathologic examination, providing vital information about the axillary nodal status of the patient and guiding further treatment. (See  <a class="medical medical_review" href="/d/html/813.html" rel="external">"Overview of management of the regional lymph nodes in breast cancer"</a>.)</p><p>The SLNB technique is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/805.html" rel="external">"Sentinel lymph node biopsy in breast cancer: Techniques"</a>.)</p><p class="headingAnchor" id="H30187371"><span class="h2">Development and validation of SLNB technique</span><span class="headingEndMark"> — </span>The SLNB technique has been developed and validated over the past three decades. It has been demonstrated to be feasible, accurate, and less morbid than axillary lymph node dissection (ALND). It has been adopted by medical centers worldwide as the standard initial approach for patients with early-stage breast cancer.</p><p>Despite variability in selection criteria and technique, a sentinel lymph node is consistently identified in approximately 96 percent of patients and predicts the status of the remaining axillary lymph nodes in ≥95 percent of patients in most series [<a href="#rid44">44,45</a>].</p><p>A systematic review of 69 trials of SLNB, including 8059 patients, showed that sentinel lymph nodes could be identified in 95 percent of patients with a false negative rate of 7.3 percent (range 0 to 29 percent) [<a href="#rid46">46</a>]. Using a combination of <a class="drug drug_general" data-topicid="9039" href="/d/drug information/9039.html" rel="external">isosulfan blue dye</a> and radioactive colloid resulted in a significantly higher success rate and lower false negative rate in sentinel node mapping compared with using isosulfan blue dye alone.</p><p>The false negative rate of SLNB was originally reported as being 5 to 10 percent (sensitivity 90 to 95 percent), but lower rates were attained by experienced surgeons [<a href="#rid44">44,47</a>]. Despite initial concerns that this false negative rate would translate into increased axillary recurrence, subsequent trials found that recurrence rates with SLNB were comparable to those with ALND [<a href="#rid43">43,48</a>].</p><p>In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial, for example, axillary recurrence after SLNB was 0.4 percent with ALND versus 0.7 percent without ALND [<a href="#rid43">43</a>]. Similar findings were demonstrated in the Veronesi study (0 percent with ALND versus 0.8 percent without ALND) [<a href="#rid48">48</a>]. The low axillary recurrence rates in these trials, even without ALND, were presumably due to the effects of adjuvant therapy (chemotherapy or radiotherapy) that may treat residual axillary disease burden. In patients who did not receive adjuvant therapy or ALND, the axillary recurrence rate was as high as 20 percent, as reported for the NSABP-04 trial [<a href="#rid49">49</a>].</p><p>SLNB is less morbid for patients than ALND. Several studies have shown that the risk of arm morbidity, particularly lymphedema, sensory loss, and shoulder abduction deficits, is significantly less for SLNB than ALND  (<a class="graphic graphic_table graphicRef109651" href="/d/graphic/109651.html" rel="external">table 1</a>) [<a href="#rid50">50-56</a>]. As an example, in one trial, the risk of lymphedema after 12 months was reported as 2 percent after SLNB alone as compared with 13 percent after SLNB with ALND [<a href="#rid50">50</a>]. In addition, SLNB identifies patients without axillary node involvement, thereby obviating the need for more extensive surgery for those patients [<a href="#rid44">44</a>].</p><p>The SLNB technique has been adopted by virtually all medical centers in the world as a standard means of axillary nodal assessment [<a href="#rid57">57,58</a>]. It is endorsed by multiple guidelines as an alternative to ALND for the diagnosis of axillary metastases in patients with clinically node-negative early breast cancer [<a href="#rid1">1,2,6,59,60</a>]. </p><p class="headingAnchor" id="H169127"><span class="h2">Pathologic analysis of nodal metastases</span><span class="headingEndMark"> — </span>Sentinel node metastases are subgrouped into isolated tumor cell clusters, micrometastases, and macrometastases based upon the size of the largest contiguous tumor deposit present in the sentinel node, as determined by routine histologic examination of slides stained by hematoxylin and eosin.</p><p>Immunohistochemistry staining with cytokeratin is not routinely indicated in the pathologic examination of sentinel lymph nodes for breast cancer. Immunohistochemistry stains can be helpful in establishing the size and extent of metastatic disease and in confirming invasive, metastatic lobular carcinoma, a cancer subtype with morphology that can be difficult to discern by hematoxylin and eosin stain alone [<a href="#rid61">61,62</a>]. The use of immunohistochemistry staining, however, is reserved for cases in which metastatic cancer of any subtype, including lobular, is suspected but cannot be confirmed based on hematoxylin and eosin stain alone.</p><p class="headingAnchor" id="H169509"><span class="h3">Isolated tumor cell clusters</span><span class="headingEndMark"> — </span>Isolated tumor cell clusters are defined as small clusters of tumor cells not greater than 0.2 mm or nonconfluent or nearly confluent clusters of cells not exceeding 200 cells in a single histologic lymph node cross section [<a href="#rid63">63</a>]. According to the Tumor, Node, Metastasis (TNM) staging system, isolated tumor cell clusters are designated as pN0(i+). Prognostically, patients with isolated tumor cell clusters appear to do as well as patients without any pathologic node involvement. Of note, the finding of isolated tumor cells or clusters in lymphatic channels as a result of iatrogenic displacement from core biopsy procedures has been observed but does not significantly change prognosis [<a href="#rid64">64-67</a>]. (See  <a class="medical medical_review" href="/d/html/800.html" rel="external">"Tumor, node, metastasis (TNM) staging classification for breast cancer"</a>.)</p><p class="headingAnchor" id="H169603"><span class="h3">Micrometastases</span><span class="headingEndMark"> — </span>Micrometastatic nodal involvement is defined as a metastatic deposit &gt;0.2 mm but ≤2.0 mm. If present, it is designated as pN1<sub>mi</sub> in the American Joint Committee on Cancer (AJCC) staging system. Patients with pN1<sub>mi</sub> breast cancer have a slightly worse prognosis compared with those with node-negative breast cancer, but micrometastases do not predict recurrence [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/d/html/800.html" rel="external">"Tumor, node, metastasis (TNM) staging classification for breast cancer"</a> and  <a class="medical medical_review" href="/d/html/782.html" rel="external">"Prognostic and predictive factors in early, non-metastatic breast cancer", section on 'Nodal involvement'</a>.)</p><p class="headingAnchor" id="H169631"><span class="h3">Macrometastases</span><span class="headingEndMark"> — </span>Macrometastatic involvement of the axillary nodes (classically designated as "node-positive") is defined by any tumor cell deposit &gt;2.0 mm. The presence of macrometastases within the axillary nodes is a well-established independent prognostic factor, with prognosis worsening with increasing nodal involvement and tumor burden. (See  <a class="medical medical_review" href="/d/html/782.html" rel="external">"Prognostic and predictive factors in early, non-metastatic breast cancer", section on 'Nodal involvement'</a>.)</p><p class="headingAnchor" id="H1815069"><span class="h3">Extranodal extension</span><span class="headingEndMark"> — </span>Extranodal (extracapsular) extension is defined as invasive tumor cells or clusters that are present outside of the lymph node capsule and parenchyma. In cases of extranodal extension, there is generally tumor present in both a subcapsular location and the adjacent extranodal fat. However, a fibrous reaction (desmoplasia) to the tumor cells may obscure tumor invasion of the extranodal fat. </p><p>Focal or minimal extracapsular extension of metastatic tumor is less significant than extensive or more obvious extranodal extension [<a href="#rid69">69</a>]. Isolated tumor cells or clusters within perinodal or axillary lymphatic channels are not considered extranodal extension. Instead, they should be measured and classified as isolated tumor cell clusters (ITCs) or micrometastases. (See <a class="local">'Isolated tumor cell clusters'</a> above and <a class="local">'Micrometastases'</a> above.)</p><p>An axillary fat tumor deposit is typically classified as a "positive node" and counts toward the total number of positive nodes that will determine if the patient should undergo ALND. One retrospective study of over 1000 patients with T1-T2cN0 breast cancer undergoing sentinel node biopsy and ALND for sentinel node metastases found that the presence of extranodal tumor deposits was strongly associated with four or more positive nonsentinel lymph nodes (odds ratio 7.15, 95% CI 4.04-12.67) among patients with one to two positive sentinel lymph nodes (n = 925) [<a href="#rid70">70</a>]. </p><p class="headingAnchor" id="H169649"><span class="h3">Occult metastatic disease</span><span class="headingEndMark"> — </span>Occult micrometastases refer to nodal metastases that are not seen on initial hematoxylin and eosin examination but are detected subsequently by additional levels or by immunohistochemical staining or reverse transcriptase polymerase chain reaction. In one study, more intensive pathologic evaluation of the nodes by deeper sectioning and immunohistochemical staining increased the yield of occult metastases and led to an overall case conversion rate of 10.3 percent in patients who had an initial negative SLNB [<a href="#rid71">71</a>]. </p><p>Occult micrometastases have no significance in terms of surgical management and patient outcomes [<a href="#rid68">68,72</a>]. Thus, routine immunohistochemistry staining or reverse transcriptase polymerase chain reaction is not recommended for the evaluation of sentinel lymph nodes in guidelines published by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, and others [<a href="#rid2">2,6,13</a>]. Histologically negative nodes that are immunohistochemistry staining or reverse transcriptase polymerase chain reaction-positive are still classified as pN0 disease in the TNM staging system for breast cancer. (See  <a class="medical medical_review" href="/d/html/800.html" rel="external">"Tumor, node, metastasis (TNM) staging classification for breast cancer"</a>.)</p><p class="headingAnchor" id="H164839"><span class="h1">MANAGEMENT AFTER SENTINEL LYMPH NODE BIOPSY</span><span class="headingEndMark"> — </span>Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) as the initial assessment of axillary nodes in patients with early breast cancer. Based upon pathologic results obtained by SLNB, we recommend no further axillary surgery for patients who meet <strong>all</strong> of the following criteria ("Z-0011-eligible" criteria) (see <a class="local">'One or two sentinel node metastases'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Clinically negative nodes based on an adequate clinical node evaluation, including imaging when necessary (eg, obesity).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A T1 or T2 (≤5 cm) primary breast cancer. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fewer than three metastatic sentinel lymph nodes on SLNB.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients undergoing breast-conserving surgery followed by whole-breast irradiation.</p><p></p><p>A completion ALND is required for patients who have:</p><p class="bulletIndent1"><span class="glyph">●</span>Three or more metastatic sentinel lymph nodes on SLNB.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One or two metastatic sentinel lymph nodes on SLNB but who do not desire whole-breast irradiation.</p><p></p><p>These recommendations are consistent with the 2014 American Society of Clinical Oncology (ASCO) guidelines [<a href="#rid1">1</a>].</p><p>In patients who are otherwise Z0011 eligible, there is no evidence to suggest that the status of the estrogen (ER) and progesterone (PR) receptors, and expression of the human epidermal growth factor 2 (HER2) receptor, is relevant to the accuracy of SLNB or to the need for completion ALND [<a href="#rid1">1</a>]. The original American College of Surgeons Oncology Group (ACOSOG) Z-0011 trial did not stratify patients based on their HER2 status. Sixteen percent of patients included in that trial had ER-negative/PR-negative tumors, and patients with ER-negative/PR-negative tumors and those with ER-positive tumors had comparable overall and disease-free survival [<a href="#rid73">73</a>]. </p><p class="headingAnchor" id="H166993"><span class="h2">No sentinel node metastasis</span><span class="headingEndMark"> — </span>We do not perform ALND in patients with early breast cancer who do not have nodal metastasis on SLNB, including those with isolated tumor cells present in the sentinel node(s).</p><p>Seven randomized trials compared patients with early breast cancer who underwent SLNB first followed by ALND only if SLNB was positive with those who underwent ALND  (<a class="graphic graphic_table graphicRef109651" href="/d/graphic/109651.html" rel="external">table 1</a>). Compared with ALND, SLNB first followed by selective ALND in patients with positive sentinel lymph nodes resulted in similar overall survival (OS), disease-free survival (DFS), and disease recurrence rates but fewer adverse events and better quality of life. This conclusion is best illustrated by the results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial, which included the largest number of patients of all the trials.</p><p>The NSABP B-32 trial enrolled 5611 early-stage breast cancer patients with clinically negative nodes and compared SLNB followed by ALND with SLNB followed by ALND only if the sentinel lymph node was positive [<a href="#rid74">74,75</a>]. SLNB was successfully performed in 97 percent of patients, and the false negative rate was 9.8 percent. No significant differences were observed in regional control, OS, or DFS between the groups at a median follow-up period of almost eight years [<a href="#rid76">76,77</a>]. </p><p class="headingAnchor" id="H2587330516"><span class="h2">Micrometastasis</span><span class="headingEndMark"> — </span>Micrometastatic nodal involvement is defined as a metastatic deposit &gt;0.2 mm but ≤2.0 mm. In patients with micrometastasis only on SLNB, no completion ALND is needed (as long as the patient otherwise fits the Z-0011 criteria). This is supported by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In the IBCSG 23-01 trial, which included 6681 patients with one or more micrometastatic sentinel nodes and no extracapsular extension, the disease-free survival at 10 years was similar with or without completion ALND (74.0 versus 76·8 percent) [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Swedish prospective multicenter cohort study SENOMIC, the event-free survival at three years was excellent in 566 patients with breast cancer and sentinel node micrometastases despite omission of ALND [<a href="#rid79">79</a>]. </p><p></p><p class="headingAnchor" id="H220673"><span class="h2">Occult metastasis</span><span class="headingEndMark"> — </span>Occult metastasis refers to tumor cells in the lymph node that are not seen on initial hematoxylin and eosin examination but are detected subsequently by examining additional levels or by performing immunohistochemistry staining or reverse transcriptase polymerase chain reaction. (See <a class="local">'Occult metastatic disease'</a> above.)</p><p>In patients with occult metastasis found by SLNB, no completion ALND is needed, and no alteration in subsequent adjuvant therapy is recommended [<a href="#rid68">68,72,80-82</a>].</p><p>Clinical trials have examined the significance of occult metastases in sentinel nodes. Blinded analysis of occult metastases in clinical trials provides prognostic data on the significance of micrometastases and isolated tumor cell clusters. The NSABP B-32 trial demonstrated that the presence of occult metastases was associated with a 1.2 percent lower OS rate and a 2.8 percent lower DFS rate; patients with occult metastases did not have a higher incidence of regional or distant recurrences [<a href="#rid68">68</a>]. The ACOSOG Z-0010 trial found a 0.6 percent lower overall survival rate in patients with occult metastases, but this was not statistically significant [<a href="#rid72">72</a>]. The two trials used different protocols for detecting occult metastases, and although the B-32 trial had higher statistical power, both trials demonstrated similar outcomes related to occult metastases. In addition, the occult metastases detected were almost entirely isolated tumor cell clusters or micrometastases and only rarely macrometastases [<a href="#rid71">71</a>]. </p><p>In a retrospective study, 93,070 patients with invasive breast adenocarcinoma and negative lymph nodes on routine pathology underwent immunohistochemistry staining to evaluate for occult nodal disease. The presence of micrometastases was associated with a worse overall survival rate (hazard ratio [HR] 1.40, 95% CI 1.28-1.53), while the presence of isolated tumor cells was not (HR 1.05, 95% CI 0.92-1.20) [<a href="#rid83">83</a>]. </p><p class="headingAnchor" id="H164859"><span class="h2">One or two sentinel node metastases</span><span class="headingEndMark"> — </span>There is compelling evidence that ALND is not necessary in most women with early-stage breast cancer who have only one or two sentinel lymph node metastases and who will receive whole-breast irradiation as part of breast-conserving therapy. If, however, whole-breast irradiation is not planned, then ALND is indicated for such patients.</p><p>Historically, patients with any nodal metastasis underwent completion ALND [<a href="#rid6">6</a>]. However, only approximately 40 percent of patients with a positive sentinel lymph node had residual disease in the axilla [<a href="#rid6">6,44,45,47,74,84-89</a>]; the rest derived no benefit from the addition of ALND. Thus, several predictive nomograms were developed to estimate the risk of additional positive nodes based on known clinical and pathologic data derived from SLNB [<a href="#rid90">90-97</a>]. Most of these nomograms included data such as the size and number of the sentinel lymph node (SLN) metastases, extranodal extension, the size and presence of lymphovascular invasion in the primary tumor, and the size of the metastatic disease in the SLN [<a href="#rid97">97</a>]. However, retrospective analyses of patients with positive SLNs who underwent completion ALND found none of the popular nomograms to be sufficiently reliable for clinical use [<a href="#rid93">93,98</a>]. </p><p>Two randomized trials, the ACOSOG Z-0011 trial and the International Breast Cancer Study Group 23-01 (IBCSG 23-01) trial, demonstrated that many of these patients with one or two metastatic sentinel nodes can safely avoid a completion ALND.</p><p class="bulletIndent1"><span class="glyph">●</span>The ACOSOG Z-0011 trial was designed to address the need for completion ALND for patients with T1 or T2 breast cancer who were clinically node negative and had fewer than three positive sentinel nodes  (<a class="graphic graphic_table graphicRef109651" href="/d/graphic/109651.html" rel="external">table 1</a>) [<a href="#rid50">50,73,99</a>]. All patients were treated with radiation to the whole breast. Compared with SLNB plus completion ALND, SLNB alone resulted in similar five-year OS rates (91.9 percent SLNB alone group versus 92.5 percent), DFS rates (82.2 SLNB alone group versus 83.9 percent), and recurrence events (four SLNB alone group versus two). The ACOSOG Z-0011 trial has been criticized for premature study termination due to low accrual and low event rates, protocol noncompliance, and a high percentage (20 percent) of patients lost to follow-up [<a href="#rid48">48,51</a>]. In addition, the ACOSOG Z-0011 trial did not account for the number of patients in each study group who had isolated tumor cell clusters, micrometastases, or macrometastases. The majority of the study population had T1 (almost 70 percent) hormone receptor-positive (85 percent) tumors, which may influence survival outcomes in ways that cannot be controlled for. Nevertheless, the ACOSOG Z-0011 trial has widely changed the practice of early breast cancer treatment. Its results have been incorporated into treatment guidelines such as the ASCO 2014 practice guidelines for SLNB [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">At a median follow-up of 9.3 years, the 10 year OS (86.3 percent SLND alone versus 83.6 percent ALND) and DFS (80.2 percent SLND alone versus 78.2 percent ALND) were statistically similar between the SLND alone group and the ALND group [<a href="#rid100">100</a>]. The cumulative incidence of ipsilateral axillary recurrences at 10 years was 1.5 percent (5 patients) in the SLND alone arm and 0.5 percent (2 patients) in the ALND arm; the 10 year cumulative incidence of local regional recurrences was 5.3 percent with SLND alone and 6.2 percent with ALND [<a href="#rid101">101</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The IBCSG 23-01 trial randomly assigned patients with a primary tumor &lt;5 cm in size and clinically nonpalpable axillary nodes to either completion ALND or no additional axillary surgery after a finding of positive sentinel lymph node(s)  (<a class="graphic graphic_table graphicRef109651" href="/d/graphic/109651.html" rel="external">table 1</a>) [<a href="#rid52">52</a>]. Only one or two sentinel nodes were positive in 85 percent of the patients. All patients had nodal metastases less than 2 mm in size, and 67 percent had micrometastases less than 1 mm. Ninety percent of patients underwent breast-conserving surgery; 10 percent underwent mastectomy. A similar proportion of patients in each group received adjuvant radiation, hormonal therapy, and chemotherapy. Approximately 90 percent of patients in both groups received whole-breast irradiation. At five years, there was no statistically significant difference in DFS rates (84 percent with ALND versus 88 percent without ALND) with OS rates (98 percent versus 97.6 percent) between the two groups. The IBCSG 23-01 trial was also closed prematurely due to low enrollment and low event rates.</p><p></p><p>Because of these two randomized trials and other studies that examined the role of ALND in managing limited axillary disease in women with early-stage clinically node-negative breast cancer, the ASCO changed its guidelines from recommending ALND for all patients with a positive sentinel lymph node (2005) to recommending against ALND for patients with fewer than three positive sentinel lymph nodes (2014). As a result, the eligibility criteria for one of the trials have become descriptive for this group of patients [<a href="#rid1">1</a>]. These so-called "Z-0011-eligible" patients are women with early-stage clinically node-negative breast cancer metastatic to one to two sentinel lymph nodes who undergo breast-conserving surgery with whole-breast radiotherapy. It is now a widespread practice that women with similarly favorable breast cancer no longer receive completion ALND.</p><p>In a prospective validation study to the ACOSOG Z-0011 trial, 793 patients underwent breast-conserving therapy for cT1-2 N0 breast cancers. Sixteen percent underwent ALND, most commonly for metastasis in ≥3 sentinel nodes or gross extracapsular extension in involved sentinel nodes [<a href="#rid102">102</a>]. For the remaining 84 percent who underwent SLNB alone, the five-year event-free survival was 93 percent (95% CI 89 to 94 percent). There were no isolated axillary recurrences, and the five-year cumulative rates of breast plus nodal and nodal plus distant recurrence rates were both 0.7 percent. Among a subset of 509 patients with known radiation therapy fields, only 21 percent of patients received both breast and nodal irradiation. The cumulative rate of nodal recurrence was 1 percent and did not differ by radiation fields.</p><p class="headingAnchor" id="H1814962"><span class="h3">Sentinel node metastasis with extranodal extension</span><span class="headingEndMark"> — </span>Although the ACOSOG Z-0011 trial established that completion ALND is not necessary for patients who have only one or two positive sentinel nodes, patients who had gross extranodal extension were excluded from the trial. Thus, completion ALND is still considered the standard of care for patients with gross extranodal extension of sentinel node metastasis, regardless of the number.</p><p>The presence of extranodal extension is associated with increased axillary nodal disease burden. The reported incidence of nonsentinel lymph node metastases in patients with extranodal extension ranged from 58 to 84 percent [<a href="#rid103">103-105</a>]. In contrast, the ACOSOG Z-0011 trial, which excluded patients with extranodal extension, reported nonsentinel nodal metastases in 27 percent of patients. In two studies, the presence of extranodal extension, regardless of size, was associated with a greater risk of having pN2 disease (four or more positive nodes) [<a href="#rid69">69,106</a>].</p><p>Some, but not all, studies also reported increased disease recurrence [<a href="#rid103">103,107</a>] and decreased survival [<a href="#rid103">103,108-112</a>] with extranodal extension. However, none of these studies was prospective. Thus, most experts recommend that all patients who are found to have extranodal extension in any number of sentinel nodes should be offered completion ALND because of the high axillary nodal disease burden associated with extranodal extension. </p><p>Other experts suggested that only extranodal extension that is &gt;2 mm should be considered an indication for ALND when applying Z0011 criteria to patients with fewer than three metastatic sentinel lymph nodes [<a href="#rid69">69</a>]. In one study, 331 patients with pT1-2, cN0 disease with &lt;3 positive SLNs underwent completion ALND. Thirty-three percent of patients with extranodal extension &gt;2 mm had ≥4 additional positive nodes at completion ALND, compared with only 9 percent of patients with extranodal extension ≤2 mm. This observation was further supported by a report of patients meeting the Z0011 criteria who had microscopic extracapsular extension (mECE) and were prospectively followed. Those patients having mECE of &lt;2 mm (n = 117) had no isolated axillary recurrences, and those having mECE of &gt;2 mm (n = 93) had a 3.2 percent isolated axillary recurrence rate at a mean of 41 months follow-up [<a href="#rid113">113</a>]. However, given that patients with any extranodal extension were excluded from the Z0011 trial, we recommend that all such patients should be considered for completion ALND until further data on survival and recurrence rate become available.</p><p class="headingAnchor" id="H1814976"><span class="h3">Sentinel node metastasis with large tumor</span><span class="headingEndMark"> — </span>Patients with large tumors (eg, T3) but clinically negative axilla were excluded from the ACOSOG Z-0011 trial. Although SLNB can be performed in such patients, conclusions drawn from the Z-0011 trial cannot be applied to such patients. Thus, completion ALND is still offered as the standard of care for any patient who has a large (&gt;5 cm or T3) tumor with any positive sentinel nodes. (See <a class="local">'Locally advanced and inflammatory breast cancer'</a> above.)</p><p class="headingAnchor" id="H166982"><span class="h2">Three or more sentinel node metastases</span><span class="headingEndMark"> — </span>For patients with three or more pathologically involved sentinel nodes, we recommend a completion ALND for staging purposes and to maximize local control [<a href="#rid2">2,6</a>]. The timing of the procedure (ie, immediate [one operation] versus delayed [two separate operations]) does not seem to affect the total lymph node yield or the rate of long-term complications (particularly lymphedema).</p><p>This recommendation is consistent with the 2014 guidelines from the ASCO [<a href="#rid1">1</a>] and is also supported by data from a 2013 systematic review that included 17 studies with at least two years of follow-up [<a href="#rid54">54</a>].</p><p>The use of ALND in breast cancer treatment is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/14984.html" rel="external">"Technique of axillary lymph node dissection"</a> and  <a class="medical medical_review" href="/d/html/813.html" rel="external">"Overview of management of the regional lymph nodes in breast cancer"</a>.)</p><p class="headingAnchor" id="H1814895"><span class="h2">Role of radiotherapy</span><span class="headingEndMark"> — </span>All of the women in the ACOSOG Z-0011 trial received whole-breast irradiation, as did 90 percent of the women in the IBCSG 23-01 trial. Given that part of the axilla is included in the treatment field with whole-breast radiation, women who received radiation in the two trials probably experienced a therapeutic effect from radiation sterilizing any residual tumor cells in the axilla [<a href="#rid114">114</a>]. The same benefit would not be conferred by partial-breast radiation unless axillary radiation was used separately to control the axilla<strong> </strong>[<a href="#rid53">53</a>]. Thus, we recommend omitting ALND in patients with one or two positive SLNs who plan to undergo whole-breast irradiation but not partial-breast irradiation until there are trials demonstrating its safety in this population. </p><p>Reported in 2014, the After Mapping of the Axilla: Radiotherapy or Surgery (AMAROS) trial was a multi-institutional trial conducted by the European Organization for the Research and Treatment of Cancer (EORTC) [<a href="#rid53">53</a>]. The trial included 4806 patients with T1 or T2, primary, unifocal, invasive breast cancer without palpable axillary lymphadenopathy. Of the 1425 patients who were found to have positive sentinel node(s) by SLNB, 744 were randomly assigned to receive ALND and 681 to receive axillary radiotherapy. Ninety-five percent of patients in both groups had one or two positive SLNs. The five-year axillary recurrence rate was 0.43 percent (0 to 0.92) in the ALND group and 1.19 percent (0.31 to 2.08) in the axillary radiation group. There were no statistically significant differences in DFS and OS between treatment groups. Lymphedema was noted significantly more often after ALND than after axillary radiation at one, three, and five years. This trial was limited by a low number of events and a short follow-up period.</p><p>The 10 year follow-up results of the AMAROS trial have been reported in abstract form [<a href="#rid115">115</a>]. After 10 years, axillary recurrence remained low and comparable between the ALND group (7/744 patients; 0.93 percent) and the axillary radiotherapy group (11/681 patients; 1.82 percent). Distant metastasis-free survival and overall survival rates were similar. More second primary cancers developed in patients treated with axillary radiotherapy (11.0 versus 7.7 percent, p = 0.035). Some of these cancers were contralateral breast cancers. Although the risk of developing a contralateral breast cancer from scatter dose from the treated ipsilateral axilla should be negligible, it will be important to see the full list of the locations of the second primary cancers to assess whether any of these cancers could have been associated with radiotherapy.</p><p>The AMAROS trial showed axillary radiation to be an acceptable alternative to ALND in patients who have positive sentinel node(s) but do not meet the Z0011 criteria. For those who meet the Z0011 criteria, axillary radiation is likely to add morbidity without conferring any additional benefit compared with whole-breast irradiation alone. Additional studies are needed before regional radiotherapy can be accepted as a standard approach for patients with axillary metastases.</p><p class="headingAnchor" id="H365981762"><span class="h1">NONAXILLARY LYMPH NODE BIOPSY</span><span class="headingEndMark"> — </span>Sentinel lymph node biopsy (SLNB) techniques can identify nonaxillary metastases (eg, internal mammary nodes and intramammary nodes) in up to 43 percent of patients, depending upon the volume/type of colloid injected, the injection technique [<a href="#rid55">55-57</a>], and the primary tumor location/size [<a href="#rid58">58</a>]. Whether identifying nonaxillary sentinel nodes is useful remains controversial since the majority of the data regarding treatment decisions and outcomes come from evaluation of only axillary nodes.</p><p class="headingAnchor" id="H24"><span class="h2">Internal mammary nodes</span><span class="headingEndMark"> — </span>Internal mammary nodes are only visualized in 20 percent of patients during SLNB and can be difficult to remove because of their location. Thus, in the absence of definitive data, dissection of the internal mammary nodes with SLNB should be considered investigational. </p><p>There is no consensus on the need for internal mammary nodal dissection in women with detection of an internal mammary node by lymphoscintigraphy [<a href="#rid6">6,59</a>]. Several trials failed to demonstrate a survival benefit with surgical dissection of internal mammary nodes [<a href="#rid116">116,117</a>], and therefore the internal mammary nodes are not routinely dissected in patients undergoing breast-conserving therapy or mastectomy with axillary lymph node dissection (ALND). </p><p>Experienced surgeons may elect to remove internal mammary nodes if they are identified during SLNB. However, surgeons with less experience removing internal mammary nodes may elect to remove an internal mammary node if it is the only identifiable sentinel node. </p><p>When internal mammary nodes are biopsied, tumor involvement is found in approximately 20 percent of patients [<a href="#rid118">118</a>]. Eight to 10 percent of patients without axillary disease are found to have regional metastases to the internal mammary nodes [<a href="#rid58">58,118-123</a>]. Positive internal mammary nodes are most commonly found with medial tumors over 2 cm in size [<a href="#rid124">124</a>]. Tumor involvement of internal mammary nodes is associated with a poor prognosis [<a href="#rid116">116,125</a>]. The diagnosis of positive internal mammary nodes may affect treatment decisions regarding adjuvant systemic therapy and regional nodal irradiation [<a href="#rid119">119</a>]. (See  <a class="medical medical_review" href="/d/html/789.html" rel="external">"Radiation therapy techniques for newly diagnosed, non-metastatic breast cancer", section on 'Regional field'</a>.)</p><p>Internal mammary nodes are only visualized in approximately 20 percent of patients during SLNB [<a href="#rid118">118</a>]. This is partly explained by limitations of the SLNB technique [<a href="#rid44">44,58,119,120,122,126</a>]. The procedure does not reliably identify involved internal mammary nodes, because of interference from radioactivity at the primary tumor site [<a href="#rid44">44</a>]. There is a high rate of technical failure (20 to 39 percent) in patients with parasternal hot spots on lymphoscintigraphy [<a href="#rid118">118,122,123</a>], and hot spots in the internal mammary region do not always represent tumor involvement [<a href="#rid58">58,120,127,128</a>]. In addition, some surgeons do not employ radioactive colloid injection and only rely on blue dye to identify the sentinel nodes.</p><p>Accordingly, additional noninvasive methods have been used to assess internal mammary nodes, including magnetic resonance (MR) imaging and positron emission tomography (PET) scanning. Breast MR imaging visualized at least one internal mammary lymph node (range 1 to 3) in 50 of 108 women with an average size of 4.5 mm (range 2 to 9 mm) [<a href="#rid129">129</a>]. However, these imaging modalities are unable to definitively identify positive nodes.</p><p>The internal mammary nodes are difficult to sample surgically even when they are identified by lymphoscintigraphy [<a href="#rid119">119</a>]. Although internal mammary lymph node biopsy can be accomplished at the time of mastectomy by splitting the fibers of the pectoralis major muscle, an internal mammary lymph node biopsy in a patient undergoing breast-conserving surgery usually requires a second incision, which is cosmetically visible through many types of clothing. Biopsy of the internal mammary node can be complicated by pneumothorax, pleural effusion, or bleeding and therefore should be performed only when, in the judgment of the surgeon, it can be performed safely [<a href="#rid120">120,122</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Intramammary nodes</span><span class="headingEndMark"> — </span>Numerous case reports document identification of intramammary lymph nodes on SLNB [<a href="#rid130">130-134</a>], although few have explored the clinical significance of this finding. Intramammary lymph nodes are present in 1 to 28 percent of women with breast cancer. Most series report a high likelihood of additional axillary nodal metastases when the intramammary nodes contain cancer [<a href="#rid135">135,136</a>]. (See  <a class="medical medical_review" href="/d/html/808.html" rel="external">"Diagnostic evaluation of suspected breast cancer"</a>.)</p><p>If intramammary nodes contain tumor, they are considered the same as a positive axillary lymph node for staging and prognostic purposes [<a href="#rid137">137</a>].</p><p class="headingAnchor" id="H2928057073"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119871.html" rel="external">"Society guideline links: Breast surgery"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86547.html" rel="external">"Patient education: Sentinel lymph node biopsy for breast cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/858.html" rel="external">"Patient education: Breast cancer guide to diagnosis and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Axillary lymph nodes in breast cancer</strong> – The status of the axillary lymph nodes is one of the most important prognostic factors in patients with breast cancer. Histologic examination of removed lymph nodes is the most accurate method for assessing nodal metastasis. An adequate clinical (and in some patients radiographic) evaluation of the axilla is required for treatment decisions in patients with invasive breast cancer. Axillary lymph node dissection (ALND) remains the standard approach for women who are clinically node positive. (See <a class="local">'Introduction'</a> above and <a class="local">'Preoperative axilla evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early-stage breast cancer</strong> – For patients with early-stage breast cancer who are clinically node negative, we recommend an initial axillary evaluation with sentinel lymph node biopsy (SLNB) rather than ALND (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Early breast cancer with clinically negative nodes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ductal carcinoma in situ</strong> – For patients with ductal carcinoma in situ (DCIS) undergoing breast-conserving surgery, we recommend <strong>not</strong> performing surgical evaluation of the axilla (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). For patients with DCIS undergoing a mastectomy, we suggest that an SLNB be performed as SLNB is not possible after a mastectomy, even if invasive disease is later found (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'DCIS with planned mastectomy or suspicious features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Select older patients</strong> – For older patients who are clinically node negative, we suggest omitting surgical evaluation of the axilla when the nodal information will not affect adjuvant treatment decisions (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Patients whose axillary status does not guide adjuvant treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeat axillary procedure</strong> – In patients who have recurrent breast cancer and previous axillary procedures (SLNB or ALND), we suggest performing a lymphoscintigraphy using 99mTc-colloidal albumin or sulfur colloid to identify the sentinel node rather than proceeding directly to an SLNB (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Recurrent breast cancer and previous axillary procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic analysis of sentinel nodes</strong> – Immunohistochemical assessment (IHC) should not be used as a routine method of evaluating sentinel nodes. IHC should be employed to definitively diagnose an area that is suspicious for, but not diagnostic of, lymph node metastases on hematoxylin and eosin (H&amp;E). (See <a class="local">'Pathologic analysis of nodal metastases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management after sentinel lymph node biopsy</strong> – The decision to proceed with completion ALND after SLNB is based on the results of the SLNB and whether the patient is "Z-0011 eligible" (defined as clinically node negative, early-stage [T1/T2, ≤5 cm] breast cancer metastatic to one to two sentinel lymph nodes [without extranodal extension] undergoing breast-conserving surgery followed by whole-breast radiotherapy) (see <a class="local">'Management after sentinel lymph node biopsy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are clinically node negative and have an SLNB that is negative or shows only isolated tumor cells, we recommend not performing completion ALND (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'No sentinel node metastasis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have an SLNB with one or two positive sentinel nodes and are "Z-0011 eligible," we recommend not performing completion axillary dissection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). If only partial-breast irradiation is planned, completion ALND should be performed. (See <a class="local">'One or two sentinel node metastases'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For women who have one or two positive sentinel nodes but are not "Z-0011 eligible" (eg, large [T3, &gt;5 cm] tumor or the presence of extranodal extension), we recommend performing completion ALND or axillary radiation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Sentinel node metastasis with large tumor'</a> above and <a class="local">'Sentinel node metastasis with extranodal extension'</a> above and <a class="local">'Role of radiotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with three or more positive sentinel nodes, we recommend performing completion ALND (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Three or more sentinel node metastases'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32:1365.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 3.2020 - March 6, 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed on April 29, 2020).</li><li><a class="nounderline abstract_t">Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010; 102:170.</a></li><li><a class="nounderline abstract_t">James TA, Palis B, McCabe R, et al. Evaluating the role of sentinel lymph node biopsy in patients with DCIS treated with breast conserving surgery. Am J Surg 2020; 220:654.</a></li><li><a class="nounderline abstract_t">Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011; 260:119.</a></li><li><a class="nounderline abstract_t">Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703.</a></li><li><a class="nounderline abstract_t">Weaver DL. Occult "micrometastases" in ductal carcinoma in situ: investigative implications for sentinel lymph node biopsy. Cancer 2003; 98:2083.</a></li><li><a class="nounderline abstract_t">Lara JF, Young SM, Velilla RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003; 98:2105.</a></li><li><a class="nounderline abstract_t">Karakatsanis A, Hersi AF, Pistiolis L, et al. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). Br J Surg 2019; 106:720.</a></li><li><a class="nounderline abstract_t">Wärnberg F, Stigberg E, Obondo C, et al. Long-Term Outcome After Retro-Areolar Versus Peri-Tumoral Injection of Superparamagnetic Iron Oxide Nanoparticles (SPIO) for Sentinel Lymph Node Detection in Breast Cancer Surgery. Ann Surg Oncol 2019; 26:1247.</a></li><li><a class="nounderline abstract_t">Lee SH, Park JW, Hwang BM. Anaphylactic Shock Following Nonionic Contrast Medium during Caudal Epidural Injection. Korean J Pain 2015; 28:280.</a></li><li><a class="nounderline abstract_t">Arslan G, Yilmaz C, Celik L, et al. Unexpected Finding on Mammography and MRI due to Accumulation of Iron Oxide Particles Used for Sentinel Lymph Node Detection. Eur J Breast Health 2019.</a></li><li><a class="nounderline abstract_t">Kaufmann M, Morrow M, von Minckwitz G, et al. Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 2010; 116:1184.</a></li><li><a class="nounderline abstract_t">Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (&gt; or = 5 cm) invasive breast cancer. Ann Surg Oncol 2001; 8:688.</a></li><li><a class="nounderline abstract_t">Wong SL, Chao C, Edwards MJ, et al. Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg 2001; 67:522.</a></li><li><a class="nounderline abstract_t">Hidar S, Bibi M, Gharbi O, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg 2009; 7:272.</a></li><li><a class="nounderline abstract_t">Singletary SE. Surgical management of inflammatory breast cancer. Semin Oncol 2008; 35:72.</a></li><li><a class="nounderline abstract_t">Klimberg VS, Rubio IT, Henry R, et al. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999; 229:860.</a></li><li><a class="nounderline abstract_t">Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000; 232:81.</a></li><li><a class="nounderline abstract_t">McMasters KM, Wong SL, Martin RC 2nd, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001; 233:676.</a></li><li><a class="nounderline abstract_t">Schrenk P, Wayand W. Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer. Lancet 2001; 357:122.</a></li><li><a class="nounderline abstract_t">Kern KA. Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid. J Am Coll Surg 2002; 195:467.</a></li><li><a class="nounderline abstract_t">Knauer M, Konstantiniuk P, Haid A, et al. Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study. J Clin Oncol 2006; 24:3374.</a></li><li><a class="nounderline abstract_t">Celebioglu F, Frisell J, Danielsson R, Bergkvist L. Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision. Eur J Surg Oncol 2007; 33:276.</a></li><li><a class="nounderline abstract_t">Heuts EM, van der Ent FW, Kengen RA, et al. Results of sentinel node biopsy not affected by previous excisional biopsy. Eur J Surg Oncol 2006; 32:278.</a></li><li><a class="nounderline abstract_t">Intra M, Trifirò G, Viale G, et al. Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Ann Surg Oncol 2005; 12:895.</a></li><li><a class="nounderline abstract_t">Taback B, Nguyen P, Hansen N, et al. Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. Ann Surg Oncol 2006; 13:1099.</a></li><li><a class="nounderline abstract_t">Newman EA, Cimmino VM, Sabel MS, et al. Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy. Ann Surg Oncol 2006; 13:52.</a></li><li><a class="nounderline abstract_t">Maaskant-Braat AJ, Voogd AC, Roumen RM, Nieuwenhuijzen GA. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat 2013; 138:13.</a></li><li><a class="nounderline abstract_t">Maaskant-Braat AJ, Roumen RM, Voogd AC, et al. Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study. Ann Surg Oncol 2013; 20:620.</a></li><li><a class="nounderline abstract_t">Vugts G, Maaskant-Braat AJ, Voogd AC, et al. Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer. Breast Cancer Res Treat 2015; 153:549.</a></li><li><a class="nounderline abstract_t">Ahmed M, Baker R, Rubio IT. Meta-analysis of aberrant lymphatic drainage in recurrent breast cancer. Br J Surg 2016; 103:1579.</a></li><li><a class="nounderline abstract_t">Poodt IGM, Vugts G, Schipper RJ, et al. Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence. Br J Surg 2019; 106:574.</a></li><li><a class="nounderline abstract_t">Poodt IGM, Walstra CJEF, Vugts G, et al. Low Risk of Development of a Regional Recurrence After an Unsuccessful Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence. Ann Surg Oncol 2019; 26:2417.</a></li><li><a class="nounderline abstract_t">Cragan JD. Teratogen update: methylene blue. Teratology 1999; 60:42.</a></li><li><a class="nounderline abstract_t">Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J 2008; 14:250.</a></li><li><a class="nounderline abstract_t">Nicklas AH, Baker ME. Imaging strategies in the pregnant cancer patient. Semin Oncol 2000; 27:623.</a></li><li><a class="nounderline abstract_t">Morita ET, Chang J, Leong SP. Principles and controversies in lymphoscintigraphy with emphasis on breast cancer. Surg Clin North Am 2000; 80:1721.</a></li><li><a class="nounderline abstract_t">Gentilini O, Cremonesi M, Trifirò G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 2004; 15:1348.</a></li><li><a class="nounderline abstract_t">Keleher A, Wendt R 3rd, Delpassand E, et al. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J 2004; 10:492.</a></li><li><a class="nounderline abstract_t">Mondi MM, Cuenca RE, Ollila DW, et al. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol 2007; 14:218.</a></li><li><a class="nounderline abstract_t">Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol 2014; 21:2506.</a></li><li><a class="nounderline abstract_t">Ban EJ, Lee JS, Koo JS, et al. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer 2011; 14:296.</a></li><li><a class="nounderline abstract_t">Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818.</a></li><li><a class="nounderline abstract_t">Borgstein PJ, Pijpers R, Comans EF, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186:275.</a></li><li><a class="nounderline abstract_t">Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006; 106:4.</a></li><li><a class="nounderline abstract_t">Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391.</a></li><li><a class="nounderline abstract_t">Giuliano AE, Morrow M, Duggal S, Julian TB. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis 2012; 29:687.</a></li><li><a class="nounderline abstract_t">Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347:567.</a></li><li><a class="nounderline abstract_t">Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252:426.</a></li><li><a class="nounderline abstract_t">Latosinsky S, Berrang TS, Cutter CS, et al. CAGS and ACS Evidence Based Reviews in Surgery. 40. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Can J Surg 2012; 55:66.</a></li><li><a class="nounderline abstract_t">Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14:297.</a></li><li><a class="nounderline abstract_t">Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15:1303.</a></li><li><a class="nounderline abstract_t">Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. JAMA 2013; 310:1385.</a></li><li><a class="nounderline abstract_t">Shimazu K, Tamaki Y, Taguchi T, et al. Lymphoscintigraphic visualization of internal mammary nodes with subtumoral injection of radiocolloid in patients with breast cancer. Ann Surg 2003; 237:390.</a></li><li><a class="nounderline abstract_t">Tanis PJ, Deurloo EE, Valdés Olmos RA, et al. Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol 2001; 8:850.</a></li><li><a class="nounderline abstract_t">Doting MH, Jansen L, Nieweg OE, et al. Lymphatic mapping with intralesional tracer administration in breast carcinoma patients. Cancer 2000; 88:2546.</a></li><li><a class="nounderline abstract_t">Harlow S, Krag D, Weaver D, Ashikaga T. Extra-Axillary Sentinel Lymph Nodes in Breast Cancer. Breast Cancer 1999; 6:159.</a></li><li><a class="nounderline abstract_t">Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542.</a></li><li><a class="nounderline abstract_t">Cantin J, Scarth H, Levine M, et al. Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy. CMAJ 2001; 165:166.</a></li><li><a class="nounderline abstract_t">Cserni G, Bianchi S, Vezzosi V, et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol 2006; 59:518.</a></li><li><a class="nounderline abstract_t">Weinberg ES, Dickson D, White L, et al. Cytokeratin staining for intraoperative evaluation of sentinel lymph nodes in patients with invasive lobular carcinoma. Am J Surg 2004; 188:419.</a></li><li class="breakAll">American Joint Committee on Cancer. Cancer Staging Manual, 7th ed, Edge SB (Ed), Springer, New York 2010. p.347.</li><li><a class="nounderline abstract_t">Carter BA, Page DL. Sentinel lymph node histopathology in breast cancer: minimal disease versus artifact. J Clin Oncol 2006; 24:1978.</a></li><li><a class="nounderline abstract_t">Youngson BJ, Liberman L, Rosen PP. Displacement of carcinomatous epithelium in surgical breast specimens following stereotaxic core biopsy. Am J Clin Pathol 1995; 103:598.</a></li><li><a class="nounderline abstract_t">Douglas-Jones AG, Verghese A. Diagnostic difficulty arising from displaced epithelium after core biopsy in intracystic papillary lesions of the breast. J Clin Pathol 2002; 55:780.</a></li><li><a class="nounderline abstract_t">Moore KH, Thaler HT, Tan LK, et al. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact? Cancer 2004; 100:929.</a></li><li><a class="nounderline abstract_t">Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011; 364:412.</a></li><li><a class="nounderline abstract_t">Gooch J, King TA, Eaton A, et al. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer. Ann Surg Oncol 2014; 21:2897.</a></li><li><a class="nounderline abstract_t">Mamtani A, Barrio AV, Goldman DA, et al. Extranodal Tumor Deposits in the Axillary Fat Indicate the Need for Axillary Dissection Among T1-T2cN0 Patients with Positive Sentinel Nodes. Ann Surg Oncol 2020; 27:3585.</a></li><li><a class="nounderline abstract_t">Weaver DL, Krag DN, Ashikaga T, et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000; 88:1099.</a></li><li><a class="nounderline abstract_t">Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011; 306:385.</a></li><li><a class="nounderline abstract_t">Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305:569.</a></li><li><a class="nounderline abstract_t">Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; 8:881.</a></li><li><a class="nounderline abstract_t">Krag DN, Julian TB, Harlow SP, et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann Surg Oncol 2004; 11:208S.</a></li><li><a class="nounderline abstract_t">Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. ASCO 2010; Abstract LBA505. J Clin Oncol 2010; 28:18s (suppl; abstr LBA505).</a></li><li><a class="nounderline abstract_t">Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11:927.</a></li><li><a class="nounderline abstract_t">Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 2018; 19:1385.</a></li><li><a class="nounderline abstract_t">Andersson Y, Bergkvist L, Frisell J, de Boniface J. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial. Br J Surg 2021; 108:1105.</a></li><li><a class="nounderline abstract_t">Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg 2009; 208:333.</a></li><li><a class="nounderline abstract_t">Chagpar A, Middleton LP, Sahin AA, et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 2005; 103:1581.</a></li><li><a class="nounderline abstract_t">Pugliese MS, Beatty JD, Tickman RJ, et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol 2009; 16:113.</a></li><li><a class="nounderline abstract_t">Kimbrough CW, McMasters KM, Quillo A, Ajkay N. Occult metastases in node-negative breast cancer: A Surveillance, Epidemiology, and End Results-based analysis. Surgery 2015; 158:494.</a></li><li><a class="nounderline abstract_t">Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med 1998; 339:941.</a></li><li><a class="nounderline abstract_t">Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15:2345.</a></li><li><a class="nounderline abstract_t">Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349:1864.</a></li><li><a class="nounderline abstract_t">Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000; 89:574.</a></li><li><a class="nounderline abstract_t">Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2:335.</a></li><li class="breakAll">Lyman GH, Kim TY, Giuliano AE. A systematic review and meta-analysis of lymphatic mapping and sentinel node biopsy (SNB) in early-stage breast cancer (ESBC) (abstract 2001). Data presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9, 2004.</li><li><a class="nounderline abstract_t">Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18:2553.</a></li><li><a class="nounderline abstract_t">Katz A, Niemierko A, Gage I, et al. Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol 2006; 93:550.</a></li><li><a class="nounderline abstract_t">Dauphine CE, Haukoos JS, Vargas MP, et al. Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2007; 14:1014.</a></li><li><a class="nounderline abstract_t">Gur AS, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg 2009; 208:229.</a></li><li><a class="nounderline abstract_t">Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003; 10:1140.</a></li><li><a class="nounderline abstract_t">Lambert LA, Ayers GD, Hwang RF, et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 2006; 13:310.</a></li><li><a class="nounderline abstract_t">Katz A, Smith BL, Golshan M, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol 2008; 26:2093.</a></li><li><a class="nounderline abstract_t">Mittendorf EA, Hunt KK, Boughey JC, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 2012; 255:109.</a></li><li><a class="nounderline abstract_t">van den Hoven I, Kuijt G, Roumen R, et al. A head to head comparison of nine tools predicting non-sentinel lymph node status in sentinel node positive breast cancer women. J Surg Oncol 2015; 112:133.</a></li><li><a class="nounderline abstract_t">Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25:3657.</a></li><li><a class="nounderline abstract_t">Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017; 318:918.</a></li><li><a class="nounderline abstract_t">Giuliano AE, Ballman K, McCall L, et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg 2016; 264:413.</a></li><li><a class="nounderline abstract_t">Morrow M, Van Zee KJ, Patil S, et al. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients. Ann Surg 2017; 266:457.</a></li><li><a class="nounderline abstract_t">Choi AH, Surrusco M, Rodriguez S, et al. Extranodal extension on sentinel lymph node dissection: why should we treat it differently? Am Surg 2014; 80:932.</a></li><li><a class="nounderline abstract_t">Changsri C, Prakash S, Sandweiss L, Bose S. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J 2004; 10:392.</a></li><li><a class="nounderline abstract_t">Abdessalam SF, Zervos EE, Prasad M, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 2001; 182:316.</a></li><li><a class="nounderline abstract_t">Choi AH, Blount S, Perez MN, et al. Size of Extranodal Extension on Sentinel Lymph Node Dissection in the American College of Surgeons Oncology Group Z0011 Trial Era. JAMA Surg 2015; 150:1141.</a></li><li><a class="nounderline abstract_t">Stranzl H, Ofner P, Peintinger F. Postoperative irradiation in breast cancer patients with one to three positive axillary lymph nodes. Is there an impact of axillary extranodal tumor extension on locoregional and distant control? Strahlenther Onkol 2006; 182:583.</a></li><li><a class="nounderline abstract_t">Neri A, Marrelli D, Roviello F, et al. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer. Ann Surg Oncol 2005; 12:246.</a></li><li><a class="nounderline abstract_t">Ilknur GB, Hilmi A, Tülay C, et al. The importance of extracapsular extension of axillary lymph node metastases in breast cancer. Tumori 2004; 90:107.</a></li><li><a class="nounderline abstract_t">Altinyollar H, Berberoğlu U, Gülben K, Irkin F. The correlation of extranodal invasion with other prognostic parameters in lymph node positive breast cancer. J Surg Oncol 2007; 95:567.</a></li><li><a class="nounderline abstract_t">Bucci JA, Kennedy CW, Burn J, et al. Implications of extranodal spread in node positive breast cancer: a review of survival and local recurrence. Breast 2001; 10:213.</a></li><li><a class="nounderline abstract_t">Drinka E, Allen P, McBride A, et al. Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer. Arch Pathol Lab Med 2015; 139:1288.</a></li><li><a class="nounderline abstract_t">Barrio AV, Downs-Canner S, Edelweiss M, et al. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. Ann Surg Oncol 2020; 27:1617.</a></li><li><a class="nounderline abstract_t">Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol 2014; 32:3600.</a></li><li class="breakAll">American Society of Clinical Oncology (ASCO). The ASCO Post. SABCS 2018: AMAROS Trial: 10-Year Follow-up of Axillary Radiotherapy or Surgery in Early-Stage Breast Cancer. Available at: http://www.ascopost.com/News/59548 (Accessed on January 14, 2019).</li><li><a class="nounderline abstract_t">Cody HS 3rd, Urban JA. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 1995; 2:32.</a></li><li><a class="nounderline abstract_t">Veronesi U, Marubini E, Mariani L, et al. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer 1999; 35:1320.</a></li><li><a class="nounderline abstract_t">Heuts EM, van der Ent FW, von Meyenfeldt MF, Voogd AC. Internal mammary lymph drainage and sentinel node biopsy in breast cancer - A study on 1008 patients. Eur J Surg Oncol 2009; 35:252.</a></li><li><a class="nounderline abstract_t">Chen RC, Lin NU, Golshan M, et al. Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J Clin Oncol 2008; 26:4981.</a></li><li><a class="nounderline abstract_t">Mansel RE, Goyal A, Newcombe RG, ALMANAC Trialists Group. Internal mammary node drainage and its role in sentinel lymph node biopsy: the initial ALMANAC experience. Clin Breast Cancer 2004; 5:279.</a></li><li><a class="nounderline abstract_t">Klauber-DeMore N, Bevilacqua JL, Van Zee KJ, et al. Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg 2001; 193:547.</a></li><li><a class="nounderline abstract_t">van der Ent FW, Kengen RA, van der Pol HA, et al. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001; 234:79.</a></li><li><a class="nounderline abstract_t">Tanis PJ, Nieweg OE, Valdés Olmos RA, et al. Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients. Br J Cancer 2002; 87:705.</a></li><li><a class="nounderline abstract_t">Shahar KH, Buchholz TA, Delpassand E, et al. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer 2005; 103:1323.</a></li><li><a class="nounderline abstract_t">Donegan WL. The influence of untreated internal mammary metastases upon the course of mammary cancer. Cancer 1977; 39:533.</a></li><li><a class="nounderline abstract_t">Noguchi M, Tsugawa K, Miwa K. Internal mammary chain sentinel lymph node identification in breast cancer. J Surg Oncol 2000; 73:75.</a></li><li><a class="nounderline abstract_t">Fabry HF, Mutsaers PG, Meijer S, et al. Clinical relevance of parasternal uptake in sentinel node procedure for breast cancer. J Surg Oncol 2004; 87:13.</a></li><li><a class="nounderline abstract_t">Carcoforo P, Sortini D, Feggi L, et al. Clinical and therapeutic importance of sentinel node biopsy of the internal mammary chain in patients with breast cancer: a single-center study with long-term follow-up. Ann Surg Oncol 2006; 13:1338.</a></li><li><a class="nounderline abstract_t">Mack M, Chetlen A, Liao J. Incidental Internal Mammary Lymph Nodes Visualized on Screening Breast MRI. AJR Am J Roentgenol 2015; 205:209.</a></li><li><a class="nounderline abstract_t">Gajdos C, Bleiweiss IJ, Drossman S, Tartter PI. Breast cancer in an intramammary sentinel node. Breast J 2001; 7:260.</a></li><li><a class="nounderline abstract_t">Tytler I, Hayes A, Kissin M. Intramammary sentinel nodes in early breast cancer: can we find them and do they matter? Eur J Surg Oncol 2003; 29:6.</a></li><li><a class="nounderline abstract_t">Jansen L, Doting MH, Rutgers EJ, et al. Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg 2000; 87:920.</a></li><li><a class="nounderline abstract_t">Upponi S, Kalra S, Poultsidis A, et al. The significance of intramammary nodes in primary breast cancer. Eur J Surg Oncol 2001; 27:707.</a></li><li><a class="nounderline abstract_t">Rull M, Fraile M, Alastrué A, et al. Histologically invaded intramammary sentinel node, but no metastases found on axillary dissection. Eur J Surg 1999; 165:1100.</a></li><li><a class="nounderline abstract_t">Intra M, Garcia-Etienne CA, Renne G, et al. When sentinel lymph node is intramammary. Ann Surg Oncol 2008; 15:1304.</a></li><li><a class="nounderline abstract_t">Pugliese MS, Stempel MM, Cody HS 3rd, et al. Surgical management of the axilla: do intramammary nodes matter? Am J Surg 2009; 198:532.</a></li><li><a class="nounderline abstract_t">Shen J, Hunt KK, Mirza NQ, et al. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer 2004; 101:1330.</a></li></ol></div><div id="topicVersionRevision">Topic 810 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24663048" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24663048" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20071685" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31964523" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evaluating the role of sentinel lymph node biopsy in patients with DCIS treated with breast conserving surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493791" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157938" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14601075" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Occult "micrometastases" in ductal carcinoma in situ: investigative implications for sentinel lymph node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14601079" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30839104" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30830536" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-Term Outcome After Retro-Areolar Versus Peri-Tumoral Injection of Superparamagnetic Iron Oxide Nanoparticles (SPIO) for Sentinel Lymph Node Detection in Breast Cancer Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26495083" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Anaphylactic Shock Following Nonionic Contrast Medium during Caudal Epidural Injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Unexpected Finding on Mammography and MRI due to Accumulation of Iron Oxide Particles Used for Sentinel Lymph Node Detection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20087962" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11597008" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Role for sentinel lymph node dissection in the management of large (&gt;or = 5 cm) invasive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11409798" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19410665" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308148" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Surgical management of inflammatory breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10363900" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Subareolar versus peritumoral injection for location of the sentinel lymph node.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10862199" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11360892" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11197404" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12375751" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849751" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178207" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246516" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Results of sentinel node biopsy not affected by previous excisional biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16195833" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791446" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16372155" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23340861" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22941173" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26358709" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27598038" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Meta-analysis of aberrant lymphatic drainage in recurrent breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30908615" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30850903" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Low Risk of Development of a Regional Recurrence After an Unsuccessful Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10413340" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Teratogen update: methylene blue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18476883" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11130469" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Imaging strategies in the pregnant cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11140869" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Principles and controversies in lymphoscintigraphy with emphasis on breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319240" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Safety of sentinel node biopsy in pregnant patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569204" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17066225" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sentinel lymph node biopsy during pregnancy: initial clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24756813" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sentinel lymph node biopsy in pregnant women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22323916" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8946902" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Lymphatic mapping and sentinel node biopsy in the patient with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9510258" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16329134" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092905" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lymphatic mapping and sentinel lymphadenectomy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22926446" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12192016" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20739842" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22269305" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : CAGS and ACS Evidence Based Reviews in Surgery. 40. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23491275" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439688" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084924" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Axillary node interventions in breast cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12616124" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lymphoscintigraphic visualization of internal mammary nodes with subtumoral injection of radiocolloid in patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776502" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861432" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lymphatic mapping with intralesional tracer administration in breast carcinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11091709" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Extra-Axillary Sentinel Lymph Nodes in Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173319" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11501455" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497870" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474439" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cytokeratin staining for intraoperative evaluation of sentinel lymph nodes in patients with invasive lobular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474439" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cytokeratin staining for intraoperative evaluation of sentinel lymph nodes in patients with invasive lobular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606969" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sentinel lymph node histopathology in breast cancer: minimal disease versus artifact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7741106" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Displacement of carcinomatous epithelium in surgical breast specimens following stereotaxic core biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12354808" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Diagnostic difficulty arising from displaced epithelium after core biopsy in intracystic papillary lesions of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14983487" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21247310" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of occult metastases on survival in node-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777858" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32488512" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Extranodal Tumor Deposits in the Axillary Fat Indicate the Need for Axillary Dissection Among T1-T2cN0 Patients with Positive Sentinel Nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699901" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791687" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21304082" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17851130" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023753" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. ASCO 2010; Abstract LBA505</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20863759" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30196031" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34010418" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19317993" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15747375" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18949520" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26032821" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Occult metastases in node-negative breast cancer: A Surveillance, Epidemiology, and End Results-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9753708" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The sentinel node in breast cancer--a multicenter validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196149" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Sentinel lymphadenectomy in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217757" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931456" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8130940" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8130940" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893286" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16705723" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Can axillary dissection be avoided in patients with sentinel lymph node metastasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17176986" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228534" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654469" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16463073" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445838" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22167004" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26258749" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A head to head comparison of nine tools predicting non-sentinel lymph node status in sentinel node positive breast cancer women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485711" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28898379" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27513155" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28650355" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25264632" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Extranodal extension on sentinel lymph node dissection: why should we treat it differently?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327491" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11720662" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26331347" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Size of Extranodal Extension on Sentinel Lymph Node Dissection in the American College of Surgeons Oncology Group Z0011 Trial Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17013571" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Postoperative irradiation in breast cancer patients with one to three positive axillary lymph nodes. Is there an impact of axillary extranodal tumor extension on locoregional and distant control?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827817" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15143982" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The importance of extracapsular extension of axillary lymph node metastases in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17226805" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The correlation of extranodal invasion with other prognostic parameters in lymph node positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14965587" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Implications of extranodal spread in node positive breast cancer: a review of survival and local recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25768237" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31820212" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135994" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Radiation field design in the ACOSOG Z0011 (Alliance) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135994" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Radiation field design in the ACOSOG Z0011 (Alliance) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7834452" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Internal mammary node status: a major prognosticator in axillary node-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10658521" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18684584" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Internal mammary lymph drainage and sentinel node biopsy in breast cancer - A study on 1008 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711171" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507173" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Internal mammary node drainage and its role in sentinel lymph node biopsy: the initial ALMANAC experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11708513" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Comprehensive review of the management of internal mammary lymph node metastases in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11420486" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12232750" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15726547" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/837336" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The influence of untreated internal mammary metastases upon the course of mammary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694642" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Internal mammary chain sentinel lymph node identification in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15221914" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Clinical relevance of parasternal uptake in sentinel node procedure for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16952022" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Clinical and therapeutic importance of sentinel node biopsy of the internal mammary chain in patients with breast cancer: a single-center study with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26102401" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Incidental Internal Mammary Lymph Nodes Visualized on Screening Breast MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11678804" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Breast cancer in an intramammary sentinel node.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12559068" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Intramammary sentinel nodes in early breast cancer: can we find them and do they matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931029" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11735164" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : The significance of intramammary nodes in primary breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10595620" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Histologically invaded intramammary sentinel node, but no metastases found on axillary dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18066627" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : When sentinel lymph node is intramammary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19800463" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Surgical management of the axilla: do intramammary nodes matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316905" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
